MeSH term
Frequency | Condition_Probility | Aged | 9 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Fatal Outcome | 4 | 0.0 |
Female | 87 | 0.0 |
Humans | 266 | 0.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Animals | 118 | 0.0 |
In Situ Hybridization, Fluorescence | 8 | 0.0 |
Mice | 35 | 0.0 |
Microsatellite Repeats | 5 | 0.0 |
Molecular Sequence Data | 52 | 0.0 |
Rats | 59 | 0.0 |
Research Support, Non-U.S. Gov't | 221 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Sequence Analysis, DNA | 9 | 0.0 |
Blotting, Southern | 7 | 0.0 |
Child | 42 | 0.0 |
Child, Preschool | 24 | 0.0 |
Cohort Studies | 4 | 0.0 |
DNA Mutational Analysis | 17 | 0.0 |
Infant | 25 | 0.0 |
Infant, Newborn | 7 | 0.0 |
Male | 74 | 0.0 |
*Mutation | 23 | 0.0 |
Phenotype | 19 | 0.0 |
Polymerase Chain Reaction | 31 | 0.0 |
Polymorphism, Single-Stranded Conformational | 28 | 1.0 |
Sensitivity and Specificity | 6 | 0.0 |
Tuberous Sclerosis/*genetics | 65 | 69.0 |
Variation (Genetics) | 3 | 0.0 |
Comparative Study | 29 | 0.0 |
Genes, Tumor Suppressor | 36 | 4.0 |
Immunoblotting | 9 | 0.0 |
Repressor Proteins/*biosynthesis | 2 | 16.0 |
Tuberous Sclerosis/genetics/*metabolism | 6 | 100.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Gene Silencing | 3 | 0.0 |
Genes, Tumor Suppressor/*physiology | 3 | 2.0 |
Loss of Heterozygosity | 24 | 2.0 |
Repressor Proteins/biosynthesis/*genetics | 2 | 13.0 |
Research Support, U.S. Gov't, P.H.S. | 99 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Up-Regulation | 3 | 0.0 |
Alleles | 13 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
DNA/metabolism | 3 | 0.0 |
Mutation | 42 | 0.0 |
Polymorphism, Genetic | 15 | 0.0 |
Temperature | 4 | 0.0 |
Time Factors | 7 | 0.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 3 | 2.0 |
Enzyme Activation | 4 | 0.0 |
*Genes, Tumor Suppressor | 30 | 2.0 |
Mitogen-Activated Protein Kinases/physiology | 2 | 1.0 |
Phosphorylation | 25 | 0.0 |
*Protein-Serine-Threonine Kinases | 10 | 1.0 |
Proto-Oncogene Proteins/physiology | 2 | 1.0 |
Repressor Proteins/genetics/*physiology | 7 | 20.0 |
Ribosomal Protein S6 Kinases/*metabolism | 3 | 12.0 |
Sirolimus/pharmacology | 6 | 8.0 |
Proteins/physiology | 2 | 1.0 |
Adult | 49 | 0.0 |
Codon, Nonsense | 3 | 2.0 |
Exons | 14 | 0.0 |
Introns | 5 | 0.0 |
Japan | 4 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
Proteins/*genetics | 38 | 2.0 |
Repressor Proteins/genetics | 24 | 16.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 5 | 0.0 |
Blotting, Northern | 8 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Flow Cytometry | 7 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
Protein Kinases/metabolism | 8 | 1.0 |
Proteins/metabolism | 8 | 0.0 |
Repressor Proteins/metabolism | 6 | 3.0 |
Ribosomal Protein S6 Kinases/metabolism | 17 | 23.0 |
*Signal Transduction | 6 | 0.0 |
Cell Division/*physiology | 2 | 1.0 |
Cell Line | 24 | 0.0 |
Proteins/genetics/*metabolism | 12 | 2.0 |
Repressor Proteins/genetics/*metabolism | 14 | 7.0 |
Transfection | 18 | 0.0 |
Tuberous Sclerosis/*genetics/physiopathology | 4 | 80.0 |
Tumor Suppressor Proteins/genetics/metabolism | 2 | 6.0 |
Chromosomes, Human, Pair 16/genetics | 14 | 15.0 |
Chromosomes, Human, Pair 9/genetics | 5 | 4.0 |
DNA Primers/chemistry | 5 | 0.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Germ-Line Mutation | 6 | 1.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Lymphangiomyomatosis/*genetics | 4 | 100.0 |
Repressor Proteins/*genetics | 67 | 26.0 |
Tuberous Sclerosis/genetics | 20 | 76.0 |
Biological Markers/analysis | 2 | 0.0 |
Immunohistochemistry | 26 | 0.0 |
Proteins/*genetics/metabolism | 8 | 3.0 |
Repressor Proteins/*genetics/metabolism | 9 | 14.0 |
Syndrome | 5 | 0.0 |
Tuberous Sclerosis/*genetics/metabolism/pathology | 2 | 100.0 |
Amino Acid Sequence | 25 | 0.0 |
Base Sequence | 47 | 0.0 |
Blotting, Western | 12 | 0.0 |
Brain/metabolism | 4 | 0.0 |
Down-Regulation | 4 | 0.0 |
Gene Deletion | 11 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Gene Library | 3 | 0.0 |
Protein Structure, Tertiary | 8 | 0.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
Signal Transduction | 19 | 0.0 |
COS Cells | 7 | 0.0 |
Pedigree | 23 | 0.0 |
Protein Binding | 16 | 0.0 |
Proteins/genetics/metabolism | 7 | 3.0 |
Tuberous Sclerosis/*genetics/pathology | 9 | 75.0 |
Two-Hybrid System Techniques | 5 | 0.0 |
Cyclins/metabolism | 2 | 0.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Middle Aged | 21 | 0.0 |
Repressor Proteins/genetics/metabolism | 2 | 2.0 |
Chromosomes, Human, Pair 17/genetics | 2 | 1.0 |
Genetic Screening | 3 | 0.0 |
Magnetic Resonance Imaging | 8 | 0.0 |
Mutation, Missense/genetics | 3 | 1.0 |
Point Mutation/genetics | 2 | 0.0 |
X Chromosome/genetics | 2 | 1.0 |
Binding Sites | 9 | 0.0 |
COS Cells/cytology | 2 | 40.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Genes, Tumor Suppressor/physiology | 4 | 8.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Molecular Chaperones | 2 | 20.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Mutation/*genetics | 8 | 0.0 |
Plasmids | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
Tuberous Sclerosis/*genetics/metabolism | 7 | 100.0 |
Amino Acid Substitution | 4 | 0.0 |
Mutation, Missense/*genetics | 3 | 1.0 |
Repressor Proteins/*genetics/*metabolism | 3 | 11.0 |
Chromosome Mapping | 19 | 0.0 |
Rats, Inbred F344 | 4 | 1.0 |
Cell Cycle | 6 | 0.0 |
Cell Line, Tumor | 6 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Hela Cells | 11 | 0.0 |
Models, Biological | 9 | 0.0 |
Repressor Proteins/chemistry/*physiology | 2 | 20.0 |
*Chromosome Mapping | 9 | 0.0 |
Crosses, Genetic | 4 | 0.0 |
Kidney Neoplasms/*genetics | 13 | 6.0 |
Lod Score | 4 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Carcinoma, Renal Cell/*genetics | 6 | 6.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Chromosomes, Human, Pair 16/*genetics | 2 | 2.0 |
*Loss of Heterozygosity | 4 | 1.0 |
Cell Division | 7 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Plasmids/metabolism | 4 | 0.0 |
Transcription, Genetic | 8 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 5 | 0.0 |
Proto-Oncogene Proteins/metabolism | 6 | 0.0 |
Ribosomal Protein S6 Kinases, 90-kDa/*metabolism | 2 | 15.0 |
Binding Sites/genetics | 2 | 0.0 |
Protein Isoprenylation | 2 | 2.0 |
Tuberous Sclerosis/genetics/metabolism | 4 | 80.0 |
Ganglioglioma/genetics | 2 | 50.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Adolescent | 21 | 0.0 |
Hyperplasia | 2 | 0.0 |
Lymphangiomyomatosis/genetics/*pathology | 3 | 100.0 |
Tuberous Sclerosis/genetics/*pathology | 4 | 80.0 |
Rats, Mutant Strains | 12 | 19.0 |
Repressor Proteins/*analysis | 4 | 57.0 |
Tuberous Sclerosis/*pathology | 2 | 28.0 |
*Cell Cycle Proteins | 3 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
DNA, Complementary/analysis | 2 | 0.0 |
*Germ-Line Mutation | 6 | 1.0 |
Hamartoma/*genetics | 5 | 45.0 |
Antibody Specificity | 3 | 0.0 |
Precipitin Tests | 12 | 0.0 |
Cloning, Molecular | 15 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Mice, Knockout | 7 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
Proteins/genetics/*physiology | 3 | 2.0 |
Brain Neoplasms/*genetics | 3 | 2.0 |
DNA Primers | 14 | 0.0 |
Ganglioglioma/*genetics | 2 | 100.0 |
*Point Mutation | 2 | 0.0 |
Exons/genetics | 12 | 0.0 |
Genes, Dominant/genetics | 3 | 2.0 |
Cell Compartmentation | 2 | 0.0 |
Cell Size/genetics | 2 | 12.0 |
*Drosophila Proteins | 4 | 0.0 |
Genes, Dominant | 12 | 1.0 |
Kidney Neoplasms/genetics | 3 | 4.0 |
*Tumor Suppressor Proteins | 6 | 0.0 |
Cell Size | 3 | 1.0 |
Drosophila | 3 | 0.0 |
English Abstract | 9 | 0.0 |
Genes, Tumor Suppressor/genetics | 3 | 1.0 |
Cell Size/*physiology | 2 | 25.0 |
Drosophila melanogaster/cytology/genetics/physiology | 2 | 100.0 |
Insulin/metabolism | 3 | 2.0 |
Mosaicism | 3 | 4.0 |
Photoreceptors, Invertebrate/*cytology/physiology/ultrastructure | 2 | 100.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Genes, Tumor Suppressor/*genetics | 10 | 3.0 |
Age Factors | 3 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Pregnancy | 13 | 0.0 |
Proteins/*metabolism | 7 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Repressor Proteins/*metabolism | 11 | 5.0 |
Tuberous Sclerosis/*metabolism/pathology | 3 | 60.0 |
DNA Mutational Analysis/*methods | 2 | 1.0 |
Gestational Age | 2 | 0.0 |
Linkage (Genetics) | 10 | 0.0 |
Prenatal Diagnosis/*methods | 2 | 1.0 |
Proteins/genetics | 15 | 2.0 |
Tuberous Sclerosis/*diagnosis/genetics | 2 | 50.0 |
DNA | 3 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 4 | 1.0 |
*Gene Deletion | 4 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Restriction Mapping | 8 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Tissue Distribution | 7 | 0.0 |
Multigene Family | 2 | 0.0 |
Polycystic Kidney, Autosomal Dominant/*genetics | 5 | 4.0 |
Proteins/genetics/physiology | 2 | 3.0 |
DNA/chemistry/genetics | 2 | 0.0 |
*Sequence Deletion | 5 | 1.0 |
Lymphangiomyomatosis/complications/*genetics | 2 | 100.0 |
Tuberous Sclerosis/complications/*genetics | 5 | 83.0 |
Heterozygote | 4 | 0.0 |
Nucleic Acid Denaturation | 2 | 2.0 |
Carrier Proteins/metabolism | 7 | 0.0 |
*Protein Biosynthesis | 2 | 0.0 |
Protein Kinases/*physiology | 4 | 7.0 |
Signal Transduction/*physiology | 5 | 0.0 |
Abnormalities, Multiple/*genetics | 2 | 0.0 |
*Chromosomes, Human, Pair 16 | 11 | 4.0 |
Karyotyping | 4 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Introns/genetics | 4 | 0.0 |
Neurons/metabolism | 5 | 1.0 |
Base Composition | 2 | 0.0 |
CpG Islands/genetics | 3 | 2.0 |
Mental Retardation/genetics | 3 | 2.0 |
Polycystic Kidney, Autosomal Dominant/genetics | 2 | 13.0 |
Recombination, Genetic | 2 | 0.0 |
Astrocytoma/genetics | 2 | 8.0 |
DNA Primers/genetics | 7 | 0.0 |
Genetic Markers | 12 | 0.0 |
DNA Mutational Analysis/methods | 3 | 1.0 |
Gene Duplication | 2 | 1.0 |
Genotype | 13 | 0.0 |
Tuberous Sclerosis/*genetics/*pathology | 5 | 100.0 |
Disease Models, Animal | 13 | 0.0 |
Kidney Neoplasms/*genetics/pathology | 2 | 2.0 |
*Ligases | 3 | 1.0 |
*Ubiquitin-Protein Ligases | 3 | 0.0 |
Protein Biosynthesis | 6 | 0.0 |
*RNA Splicing | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Repressor Proteins/analysis | 2 | 22.0 |
Alternative Splicing | 3 | 0.0 |
Chromosomes, Human, Pair 9 | 6 | 3.0 |
Point Mutation | 5 | 0.0 |
Proteins/*genetics/physiology | 3 | 4.0 |
Repressor Proteins/*genetics/physiology | 2 | 14.0 |
Rabbits | 4 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Peutz-Jeghers Syndrome/genetics/*metabolism | 2 | 100.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Rats, Inbred Strains | 2 | 0.0 |
Heteroduplex Analysis | 2 | 2.0 |
In Situ Hybridization | 4 | 0.0 |
Chromosomes, Human, Pair 16 | 11 | 8.0 |
Genetic Counseling | 2 | 1.0 |
Neoplastic Syndromes, Hereditary/*genetics | 2 | 4.0 |
Rats, Mutant Strains/*genetics | 2 | 66.0 |
Exons/*genetics | 4 | 1.0 |
Sequence Deletion | 7 | 0.0 |
Dogs | 2 | 0.0 |
*Linkage (Genetics) | 4 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Family | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Phosphoproteins/metabolism | 6 | 0.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
Biopsy | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Abnormalities/genetics | 2 | 10.0 |
Cerebral Cortex/*abnormalities | 2 | 25.0 |
Gene Expression | 12 | 0.0 |
Neurocutaneous Syndromes/*genetics | 2 | 100.0 |
Seizures/etiology | 3 | 15.0 |
Tuberous Sclerosis/complications/genetics | 3 | 75.0 |
Brain/pathology | 5 | 1.0 |
Frameshift Mutation | 3 | 0.0 |
Mutation, Missense | 2 | 0.0 |
RNA Splicing/*genetics | 2 | 2.0 |
Cell Membrane/chemistry | 2 | 1.0 |
*Disease Models, Animal | 4 | 1.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/genetics | 2 | 3.0 |
Muscle, Skeletal/metabolism | 2 | 1.0 |
*Mosaicism | 2 | 3.0 |
Point Mutation/*genetics | 2 | 0.0 |
*Gene Expression Regulation | 4 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 3 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Tuberous Sclerosis/*complications/*genetics | 3 | 75.0 |
Kidney/pathology | 3 | 2.0 |
Kidney Neoplasms/genetics/*pathology | 2 | 16.0 |
Homozygote | 4 | 0.0 |
Germ-Line Mutation/*genetics | 2 | 1.0 |
Haplotypes/genetics | 3 | 0.0 |
Loss of Heterozygosity/genetics | 3 | 2.0 |
Mosaicism/*genetics | 2 | 5.0 |
Nuclear Family | 2 | 0.0 |
Repressor Proteins/immunology/*metabolism | 2 | 66.0 |
Tuberous Sclerosis/*metabolism | 3 | 75.0 |
*Deoxyribonuclease (Pyrimidine Dimer) | 2 | 100.0 |
Endodeoxyribonucleases/*genetics | 2 | 10.0 |
*Escherichia coli Proteins | 3 | 1.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Molecular Weight | 2 | 0.0 |
Repressor Proteins/*physiology | 5 | 4.0 |
Cerebral Cortex/abnormalities/pathology | 2 | 66.0 |
*Chromosomes, Human, Pair 9 | 7 | 2.0 |
*Alleles | 2 | 0.0 |
Carcinogens | 2 | 2.0 |
Carcinoma, Renal Cell/chemically induced/*genetics | 2 | 50.0 |
Diethylnitrosamine/analogs & derivatives | 2 | 100.0 |
Kidney Neoplasms/chemically induced/*genetics | 3 | 50.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Receptors, Somatostatin/*genetics | 2 | 7.0 |
Apoptosis/genetics | 2 | 0.0 |
Cell Cycle/physiology | 2 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
DNA Probes | 2 | 0.0 |
*Chromosomes, Human, Pair 13 | 2 | 1.0 |
Genetic Techniques | 2 | 2.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Ribosomal Protein S6/metabolism | 3 | 42.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Codon/genetics | 2 | 0.0 |
DNA Transposable Elements | 2 | 1.0 |
GTPase-Activating Proteins | 4 | 2.0 |
Proteins/chemistry/genetics | 2 | 7.0 |
Repressor Proteins/chemistry/*genetics | 4 | 22.0 |
Conserved Sequence | 2 | 0.0 |
Tuberous Sclerosis/diagnosis/*genetics/metabolism | 2 | 100.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Sequence Deletion/*genetics | 2 | 1.0 |
GTP-Binding Proteins/*metabolism | 2 | 0.0 |
rap GTP-Binding Proteins | 7 | 8.0 |
Gene Rearrangement | 2 | 0.0 |
Fetal Death | 2 | 5.0 |
Organ Specificity | 3 | 0.0 |
ras GTPase-Activating Proteins | 3 | 2.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Lymphocytes | 2 | 1.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Repressor Proteins/*biosynthesis/genetics | 2 | 18.0 |
Conserved Sequence/genetics | 2 | 1.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
RNA Splicing | 2 | 0.0 |
Drosophila Proteins/genetics/metabolism | 2 | 10.0 |
Animals, Genetically Modified | 2 | 0.0 |
Carcinoma/*genetics | 2 | 1.0 |
Gene Transfer Techniques | 2 | 0.0 |
Neoplasms, Experimental/*genetics | 2 | 16.0 |
*Chromosome Deletion | 7 | 0.0 |
Gene Frequency | 2 | 0.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Brain/cytology/*metabolism/pathology | 2 | 33.0 |
Reference Values | 2 | 0.0 |
Fishes, Poisonous/*genetics | 2 | 18.0 |
*Heterozygote | 2 | 0.0 |
Angiomyolipoma/genetics | 2 | 66.0 |
Rhabdomyoma/genetics | 2 | 100.0 |
Tuberous Sclerosis/etiology/*genetics | 2 | 100.0 |
Bacteriophage P1/genetics | 2 | 8.0 |
Sequence Tagged Sites | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Genetic Diseases, Inborn/*genetics | 2 | 3.0 |
Gene Expression Regulation, Neoplastic/*physiology | 2 | 1.0 |
Genes, Lethal | 3 | 3.0 |
Models, Genetic | 4 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
Mice/*genetics | 2 | 0.0 |
*Genes, Suppressor | 2 | 8.0 |
*Proteins | 2 | 0.0 |
14-3-3 Proteins | 4 | 2.0 |
Homeodomain Proteins/genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Biological Transport | 2 | 0.0 |
Cell Proliferation | 3 | 1.0 |
Neuropeptides/*metabolism | 3 | 3.0 |
Protein Kinases/*metabolism | 5 | 1.0 |
Proteins/*physiology | 2 | 1.0 |
1-Phosphatidylinositol 3-Kinase/*physiology | 2 | 3.0 |
Cell Aging | 2 | 2.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Proteins/*genetics/pharmacology | 3 | 42.0 |
Repressor Proteins/*genetics/pharmacology | 3 | 100.0 |
Tuberous Sclerosis/*complications/genetics | 2 | 100.0 |
Gene Therapy/*methods | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Monomeric GTP-Binding Proteins/*metabolism | 2 | 13.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Rats, Long-Evans | 2 | 4.0 |
In Vitro | 2 | 0.0 |
Drosophila melanogaster/genetics/growth & development/metabolism | 2 | 66.0 |
